These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 25623736)

  • 1. The FOCUS trial: cognitive remediation plus standard treatment versus standard treatment for patients at ultra-high risk for psychosis: study protocol for a randomised controlled trial.
    Glenthøj LB; Fagerlund B; Randers L; Hjorthøj CR; Wenneberg C; Krakauer K; Vosgerau A; Gluud C; Medalia A; Roberts DL; Nordentoft M
    Trials; 2015 Jan; 16():25. PubMed ID: 25623736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive remediation plus standard treatment versus standard treatment alone for individuals at ultra-high risk of developing psychosis: Results of the FOCUS randomised clinical trial.
    Glenthøj LB; Mariegaard LS; Fagerlund B; Jepsen JRM; Kristensen TD; Wenneberg C; Krakauer K; Medalia A; Roberts DL; Hjorthøj C; Nordentoft M
    Schizophr Res; 2020 Oct; 224():151-158. PubMed ID: 32873460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive remediation versus active computer control in bipolar disorder with psychosis: study protocol for a randomized controlled trial.
    Lewandowski KE; Sperry SH; Ongur D; Cohen BM; Norris LA; Keshavan MS
    Trials; 2016 Mar; 17(1):136. PubMed ID: 26969299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mindfulness-based social cognition training (SocialMIND) versus psychoeducational multicomponent intervention for people with a first episode of psychosis: a study protocol for a randomised controlled trial.
    Mediavilla R; Muñoz-Sanjose A; Rodriguez-Vega B; Bayon C; Palao A; Lahera G; Sanchez-Castro P; Roman E; Cebolla S; de Diego A; Pastor JM; Bravo-Ortiz MF
    BMC Psychiatry; 2019 Jul; 19(1):233. PubMed ID: 31357965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial.
    Bolt LK; Amminger GP; Farhall J; McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Allott KA
    Schizophr Res; 2019 Apr; 206():67-74. PubMed ID: 30558978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection and early treatment of subjects at high risk of clinical psychosis: Definitions and recommendations].
    Michel C; Toffel E; Schmidt SJ; Eliez S; Armando M; Solida-Tozzi A; Schultze-Lutter F; Debbané M
    Encephale; 2017 May; 43(3):292-297. PubMed ID: 28347521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis.
    Velthorst E; Nieman DH; Becker HE; van de Fliert R; Dingemans PM; Klaassen R; de Haan L; van Amelsvoort T; Linszen DH
    Schizophr Res; 2009 Apr; 109(1-3):60-5. PubMed ID: 19272756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Cognitive Changes in Young Individuals at Ultrahigh Risk for Psychosis.
    Lam M; Lee J; Rapisarda A; See YM; Yang Z; Lee SA; Abdul-Rashid NA; Kraus M; Subramaniam M; Chong SA; Keefe RSE
    JAMA Psychiatry; 2018 Sep; 75(9):929-939. PubMed ID: 30046827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative Neuro-social cognitive Strategy Programme for Instilling REcovery (INSPIRE): a community-based cognitive remediation trial-study procotol.
    Tan BL; Tan N; Koh V; Poh L; Medalia A
    BMC Psychiatry; 2024 Sep; 24(1):621. PubMed ID: 39300363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised controlled trial of cognitive behaviour therapy versus non-directive reflective listening for young people at ultra high risk of developing psychosis: The detection and evaluation of psychological therapy (DEPTh) trial.
    Stain HJ; Bucci S; Baker AL; Carr V; Emsley R; Halpin S; Lewin T; Schall U; Clarke V; Crittenden K; Startup M
    Schizophr Res; 2016 Oct; 176(2-3):212-219. PubMed ID: 27554197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive functioning in at-risk mental states for psychosis and 2-year clinical outcome.
    Simon AE; Grädel M; Cattapan-Ludewig K; Gruber K; Ballinari P; Roth B; Umbricht D
    Schizophr Res; 2012 Dec; 142(1-3):108-15. PubMed ID: 23025995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurocognitive predictors of transition to psychosis: medium- to long-term findings from a sample at ultra-high risk for psychosis.
    Lin A; Yung AR; Nelson B; Brewer WJ; Riley R; Simmons M; Pantelis C; Wood SJ
    Psychol Med; 2013 Nov; 43(11):2349-60. PubMed ID: 23388122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study protocol: a randomised controlled trial of cognitive remediation for a national cohort of forensic mental health patients with schizophrenia or schizoaffective disorder.
    O'Reilly K; Donohoe G; O'Sullivan D; Coyle C; Mullaney R; O'Connell P; Maddock C; Nulty A; O'Flynn P; O'Connell C; Kennedy HG
    BMC Psychiatry; 2016 Jan; 16():5. PubMed ID: 26759167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying neurocognitive markers for outcome prediction of global functioning in individuals with first-episode and ultra-high-risk for psychosis.
    Sawada K; Kanehara A; Sakakibara E; Eguchi S; Tada M; Satomura Y; Suga M; Koike S; Kasai K
    Psychiatry Clin Neurosci; 2017 May; 71(5):318-327. PubMed ID: 28294477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurocognitive impairments in individuals at ultra-high risk for psychosis: Who will really convert?
    Bang M; Kim KR; Song YY; Baek S; Lee E; An SK
    Aust N Z J Psychiatry; 2015 May; 49(5):462-70. PubMed ID: 25425742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interview and questionnaire assessment of cognitive impairment in subjects at ultra-high risk for psychosis: Associations with cognitive test performance, psychosocial functioning, and positive symptoms.
    Randers L; Fagerlund B; Jepsen JRM; Nordholm D; Krakauer K; Hjorthøj C; Glenthøj B; Nordentoft M
    Psychiatry Res; 2020 Dec; 294():113498. PubMed ID: 33157481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls.
    Korver N; Nieman DH; Becker HE; van de Fliert JR; Dingemans PH; de Haan L; Spiering M; Schmitz N; Linszen DH
    Aust N Z J Psychiatry; 2010 Mar; 44(3):230-6. PubMed ID: 20180725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Social cognition in clinical "at risk" for psychosis and first episode psychosis populations.
    Thompson A; Papas A; Bartholomeusz C; Allott K; Amminger GP; Nelson B; Wood S; Yung A
    Schizophr Res; 2012 Nov; 141(2-3):204-9. PubMed ID: 22959742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifamily group psychoeducation and cognitive remediation for first-episode psychosis: a randomized controlled trial.
    Breitborde NJ; Moreno FA; Mai-Dixon N; Peterson R; Durst L; Bernstein B; Byreddy S; McFarlane WR
    BMC Psychiatry; 2011 Jan; 11():9. PubMed ID: 21226941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol.
    Qurashi I; Chaudhry IB; Khoso AB; Farooque S; Lane S; Husain MO; Chu S; Sarginson J; Hamarani M; Naqvi HA; Razzaque B; Minhas FA; Yung AR; Deakin JFW; Husain N
    Trials; 2017 Nov; 18(1):524. PubMed ID: 29121974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.